Chinese Registry of Rheumatoid Arthritis (CREDIT) VI: Temporal Trends in Patients With Early Rheumatoid Arthritis and Moderate‐To‐Severe Disease Activity ‐ A Multicenter Cohort Study of Treatment Strategies and Outcomes
International Journal of Rheumatic Diseases · 2025
DOI: 10.1111/1756-185x.70066 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift International Journal of Rheumatic Diseases, 2025. Verfasst von Yafang Deng und 18 weiteren Autor:innen. Beteiligte Einrichtung: School of Medicine, Tsinghua Medicine, Tsinghua University, Beijing, China. Hauptthemen laut MEDLINE: Arthritis, Rheumatoid, Antirheumatic Agents, Biological Products. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 37 Literaturangaben. Gefördert von: The Chinese National Key Technology R&D Program, Ministry of Science and Technology, CAMS Innovation Fund for Medical Sciences (CIFMS), National High Level Hospital Clinical Research Funding.
Abstract (Originalsprache)
Aim
The continuous update of international guidelines and enhanced availability of biological disease‐modifying antirheumatic drugs (bDMARDs) and targeted synthetic DMARDs (tsDMARDs) have made a significant impact on the diagnosis and treatment of early rheumatoid arthritis (ERA). This study aims to systematically evaluate the current treatment strategies and outcomes within a large‐scale cohort of patients with ERA.
Methods
Data from the Chinese Registry of Rheumatoid Arthritis (CREDIT), a large multicenter Chinese registry of RA, were collected to analyze temporal trends in clinical profiles, therapeutic strategies, and treatment outcomes among patients with ERA.
Results
From November 2016 to October 2023, A total of 2722 patients with follow‐up information for 6 months were included. The use of methotrexate (MTX) increased annually and has become the predominant DMARD as the initial treatment. Following initial therapy, 1059 (38.9%) patients achieved the therapeutic target of low disease activity and remission. Age ≥ 50 years (adjusted OR 0.70 [95% CI 0.59–0.83]; p < 0.001), high baseline disease activity (adjusted OR 0.48 [95% CI 0.41–0.57]; p < 0.001), csDMARD monotherapy other than MTX (adjusted OR 0.55 [95% CI 0.41–0.73]; p < 0.001), and the use of b/tsDMARDs without a csDMARD combination (adjusted OR 0.57 [95% CI 0.36–0.87]; p = 0.011) were associated with lower target attainment rates. For patients who did not achieve the treatment target after initial therapy, the use of b/tsDMARDs increased after 2020, although the extent of therapeutic escalation remained suboptimal.
Conclusion
Treatment of patients with ERA in China has become more standardized. Adherence to guideline‐directed therapeutic regimens has emerged as a significant determinant of therapeutic target achievement. The increased prevalence of b/tsDMARDs would benefit more patients in ameliorating the disease.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Medicine, Tsinghua Medicine, Tsinghua University, Beijing, China.
- Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital (PUMCH), Chinese Academy of Medical Sciences and Peking Union Medical College; National Clinical Research Center for Dermatologic…
- Department of Rheumatology, The Affiliated Hospital of Inner Mongolia Medical College, Hohhot, Inner Mongolia, China.
- Department of Rheumatology, The First People's Hospital of Yunnan Province, the Affiliated Hospital of Kunming University of Science and Technology, Kunming, Yunnan, China.
- Department of Rheumatology and Immunology, First Affiliated Hospital (Southwest Hospital) of Army Medical University, Chongqing, China.
- Department of Rheumatology and Immunology, People's Hospital of Xinjiang Uygur Autonomous Region, Urumqi, Xinjiang, China.
ORCID-Profile: Yafang Deng, Chen Yu, Jian Xu, Hanyou Mo, Nan Jiang, Qian Wang, Xinping Tian
Förderung
- The Chinese National Key Technology R&D Program, Ministry of Science and Technology
- CAMS Innovation Fund for Medical Sciences (CIFMS)
- National High Level Hospital Clinical Research Funding
- State Key Laboratory Special Fund
Zitieren
APA
Deng, Y., Qiao, L., Li, H., Yu, C., Jin, S., Wang, J., Zou, Q., Wu, L., Duan, X., Xu, J., Mo, H., Jiang, Z., Jiang, N., Wang, Y., Zeng, X., Li, M., Wang, Q., Tian, X., & CREDIT Co‐authors (2025). Chinese Registry of Rheumatoid Arthritis (CREDIT) VI: Temporal Trends in Patients With Early Rheumatoid Arthritis and Moderate‐To‐Severe Disease Activity ‐ A Multicenter Cohort Study of Treatment Strategies and Outcomes. International Journal of Rheumatic Diseases. https://doi.org/10.1111/1756-185x.70066
Vancouver
Deng Y, Qiao L, Li H, Yu C, Jin S, Wang J, et al. Chinese Registry of Rheumatoid Arthritis (CREDIT) VI: Temporal Trends in Patients With Early Rheumatoid Arthritis and Moderate‐To‐Severe Disease Activity ‐ A Multicenter Cohort Study of Treatment Strategies and Outcomes. International Journal of Rheumatic Diseases. 2025. doi:10.1111/1756-185x.70066
BibTeX
@article{Deng2025,
author = {Deng, Yafang and Qiao, Lin and Li, Hongbin and Yu, Chen and Jin, Shangyi and Wang, Jing and Zou, Qinghua and Wu, Lijun and Duan, Xinwang and Xu, Jian and Mo, Hanyou and Jiang, Zhenyu and Jiang, Nan and Wang, Yanhong and Zeng, Xiaofeng and Li, Mengtao and Wang, Qian and Tian, Xinping and CREDIT Co‐authors, CREDIT Co‐authors},
title = {Chinese Registry of Rheumatoid Arthritis (CREDIT) VI: Temporal Trends in Patients With Early Rheumatoid Arthritis and Moderate‐To‐Severe Disease Activity ‐ A Multicenter Cohort Study of Treatment Strategies and Outcomes},
journal = {International Journal of Rheumatic Diseases},
year = {2025},
doi = {10.1111/1756-185x.70066}
}
EUVIMED